Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/14/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 08/14/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 08/14/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 08/13/26 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
|
  |
118 |
| 08/13/26 | 8-K | Current report |
|
|
9 |
| 08/12/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
6 | |
| 08/12/26 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 07/31/26 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
|
4 | |
| 07/27/26 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
|
6 | |
| 07/23/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
7 |
